Search

Your search keyword '"Miao, Mengrong"' showing total 33 results
Start Over Author "Miao, Mengrong"
33 results on '"Miao, Mengrong"'

1. General anesthetic action profile on the human prefrontal cortex cells through comprehensive single-cell RNA-seq analysis

Author

Chang, Enqiang, Wang, Yangyang, Zhu, Ruilou, Wu, Lingzhi, Yang, Yitian, Zeng, Shuang, Li, Ningtao, Ruan, Xiaoguo, Sun, Mingyang, Zhang, Wei, Zhou, Jun, Miao, Mengrong, Zhi, Hui, Zhao, Hailin, Chen, Qian, Sun, Qizhe, Chang, Emer, Chang, Albert, Zhang, Tingting, He, Xinfang, Liu, Kan, Ma, Songhua, Zhu, Weizhong, Zhang, Youming, Magnani, Luca, Ma, Daqing, and Zhang, Jiaqiang

Published
2023
Full Text
View/download PDF

21. General Anesthetic Action Profile on the Human Prefrontal Cortex Cells Through Comprehensive Single-Cell RNA-Seq Analysis

Author

Chang, Enqiang, primary, Wang, Yangyang, additional, Zhu, Ruilou, additional, Wu, Lingzhi, additional, Yang, Yitian, additional, Zeng, Shuang, additional, Li, Ningtao, additional, Ruan, Xiaoguo, additional, Sun, Mingyang, additional, Zhang, Wei, additional, Zhou, Jun, additional, Miao, Mengrong, additional, Zhi, Hui, additional, Zhao, Hailin, additional, Chen, Qian, additional, Sun, Qizhe, additional, Chang, Emer, additional, Chang, Albert, additional, Zhang, Tingting, additional, He, Xinfang, additional, Liu, Kan, additional, Ma, Songhua, additional, Zhu, Weizhong, additional, Zhang, Youming, additional, Magnani, Luca, additional, Ma, Daqing, additional, and Zhang, Jiaqiang, additional

Published
2022
Full Text
View/download PDF

32. Metformin monotherapy versus predominantly older non‐metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management.

Author

Sun, Mingyang, Lu, Zhongyuan, Chen, Wan‐Ming, Lv, Shuang, Fu, Ningning, Yang, Yitian, Wang, Yangyang, Miao, Mengrong, Wu, Szu‐Yuan, and Zhang, Jiaqiang

Subjects
*METFORMIN, *TYPE 2 diabetes, *HYPOGLYCEMIC agents, *PROPENSITY score matching, *CEREBROVASCULAR disease, *DRUGS
Abstract

Aim Methods Results Conclusion Choosing the initial treatment for type 2 diabetes (T2D) is pivotal, requiring consideration of solid clinical evidence and patient characteristics. Despite metformin's historical preference, its efficacy in preventing cerebrovascular events lacked empirical validation. This study aimed to evaluate the associations between first‐line monotherapy (metformin or non‐metformin antidiabetic medications) and cerebrovascular complications in patients with T2D without diabetic complications.We analysed 9090 patients with T2D without complications who were prescribed either metformin or non‐metformin medications as initial therapy. Propensity score matching ensured group comparability. Cox regression analyses, stratified by initial metformin use, assessed cerebrovascular disease risk, adjusting for multiple covariates and using competing risk analysis. Metformin exposure was measured using cumulative defined daily doses.Metformin users had a significantly lower crude incidence of cerebrovascular diseases compared with non‐users (p < .0001). Adjusted hazard ratios (aHRs) consistently showed an association between metformin use and a lower risk of overall cerebrovascular diseases (aHRs: 0.67‐0.69) and severe events (aHRs: 0.67‐0.69). The association with reduced risk of mild cerebrovascular diseases was significant across all models (aHRs: 0.73‐0.74). Higher cumulative defined daily doses of metformin correlated with reduced cerebrovascular risk (incidence rate ratio: 0.62‐0.94, p < .0001), indicating a dose‐dependent effect.Metformin monotherapy is associated with a reduced risk of cerebrovascular diseases in early‐stage T2D, highlighting its dose‐dependent efficacy. However, the observed benefits might also be influenced by baseline differences and the increased risks associated with other medications, such as sulphonylureas. These findings emphasize the need for personalized diabetes management, particularly in mitigating cerebrovascular risk in early T2D stages. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Contemporary external beam radiotherapy boost or high dose-rate brachytherapy boost for cervical cancer: a propensity-score-matched, nationwide, population-based cohort study.

Author

Zhang J, Sun M, Li N, Miao M, Yang Y, Hsu HC, Chen HM, and Wu SY

Abstract

To estimate the survival effects of contemporary external beam radiotherapy (EBRT) boost modalities (intensity-modulated radiation therapy or volumetric modulated arc therapy) and high dose-rate brachytherapy (HDR-BT) boost in patients with cervical cancer (CC). Patients who had been diagnosed as having CC were recruited from the Taiwan Cancer Registry Database. Propensity score matching was performed, and Cox proportional-hazards model curves were used to analyze the all-cause mortality of patients who received standard whole-pelvis irradiation with different boost modalities. The matching process yielded a final cohort of 1,630 patients (815 in the EBRT boost and HDR-BT boost groups, respectively) eligible for further analysis. The multivariate Cox regression analyses indicated that the adjusted hazard ratio (95% confidence intervals) for EBRT boost compared with HDR-BT boost was 1.62 (1.43-1.84). Multivariable analysis revealed that the independent poor prognostic factors of all-cause mortality among patients with CC were adenocarcinoma, no chemotherapy, Charlson comorbidity index score ≥ 1, age ≥ 60 years, and advanced International Federation of Gynecology and Obstetrics stage. HDR-BT boost may be more beneficial than contemporary EBRT boost in selected patients with CC., Competing Interests: None., (AJCR Copyright © 2021.)

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results